Abstract
Background
To review treatment outcomes from real-world data of patients with neovascular age-related macular degeneration (nAMD) treated with intravitreal aflibercept (IVT-AFL) injection.
Methods
RAINBOW (ClinicalTrials.gov, NCT02279537) is an ongoing, observational, 4-year study to monitor the effectiveness and safety of IVT-AFL in patients with nAMD in clinical practice in France. Treatment-naïve patients diagnosed with nAMD who had been prescribed IVT-AFL by their treating physician were eligible. The regimens of interest were regular treatment interval cohort (patients who received three initial monthly IVT-AFL injections followed by regular injections every 2 months) and two irregular treatment interval cohorts (with and without three initial monthly injections). Here we describe results at 24 months in patients according to IVT-AFL treatment regimen.
Results
The mean change in best-corrected visual acuity (BCVA) with IVT-AFL from baseline to 24 months was + 3.0 letters in the overall population (P < 0.05 vs baseline). The mean change was positive for the regular and irregular treatment interval cohorts with initial doses (+ 4.9 and + 4.0 letters, respectively; P < 0.05 vs baseline) and negative for the irregular treatment interval cohort without initial doses (− 2.5 letters; P = 0.365 vs baseline) at 24 months. The mean overall number of IVT-AFL injections over 12 and 24 months was 6.0 and 8.8, respectively. The most common ocular adverse events were lack of efficacy (6.3%), vitreous floaters (2.7%), and increased lacrimation (1.7%).
Conclusions
In the real-world RAINBOW study, visual outcomes observed at 24 months were consistent with results from the primary endpoint at 12 months. In this study, treatment-naïve patients who received three initial IVT-AFL doses and regular IVT-AFL treatment over the first 24 months experienced better visual outcomes than patients who received no initial doses and an irregular treatment regimen.
Trial registration
www.ClinicalTrials.gov (NCT02279537). Registered 29 October 2014.
Keywords: Intravitreal aflibercept, Neovascular age-related macular degeneration, France, Real-world, Observational
Background
There are two forms of age-related macular degeneration (AMD), the neovascular and the dry forms [1]. Anti-vascular endothelial growth factor (anti-VEGF) agents, such as intravitreal aflibercept (IVT-AFL) and ranibizumab, are available for the treatment of neovascular age-related macular degeneration (nAMD), and the goal of disease management beyond the first year is to maintain or improve functional and anatomical gains while minimizing the burden on patients of clinic visits and injections [2]. Although rapid visual and anatomic improvements can be achieved in the first year of anti-VEGF treatment, regression to baseline after initial gains is not uncommon [2]. Findings from the VEGF Trap-Eye Investigation of Efficacy and Safety in Wet AMD (VIEW) studies showed that, in the second year of treatment, the dosing interval for IVT-AFL can be adjusted according to the patient’s response to treatment, without clinically meaningful loss of visual gains [3, 4].
Before IVT-AFL was authorized in Europe in 2012, anti-VEGF treatments for nAMD in France were administered as needed (pro re nata) [5]. The introduction of IVT-AFL led to changes in standard clinical practice from reactive to proactive treatment protocols/regimens. As clinicians became proficient with newly available anti-VEGF treatments for nAMD, injection intervals varied substantially, as did adherence to the indicated initiation of IVT-AFL with three initial monthly doses [6]. In the Real Life of intravitreal Aflibercept In FraNce: oBservatiOnal study in Wet AMD (RAINBOW) study, patients treated with IVT-AFL for nAMD were expected to receive three initial monthly injections followed by injections every 2 months for the first 12 months, with extensions based on visual and anatomic outcomes thereafter [4]. The purpose of this study was not to identify differences in clinical practices before and after any changes in approved dosing for IVT-AFL, but rather to describe clinically led variations in treatment practices in France and understand any impact of those on patient outcomes.
Currently, there is limited real-world evidence demonstrating how nAMD is managed in daily clinical practice in France. Real-world evidence can complement clinical trial data by providing information on the effectiveness of a treatment under real-world conditions that can support clinical management decisions and improve patient outcomes [7, 8]. Here, we report results from the second year of the RAINBOW, an ongoing study collecting effectiveness and safety data from patients with nAMD treated with IVT-AFL in clinical practice in France.
Methods
Study design
RAINBOW (NCT02279537) is an observational, 4-year study designed to monitor the effectiveness and safety of IVT-AFL in patients with nAMD in clinical practice. Patients were enrolled from 55 centers across France consisting of private, hospital and mixed-type clinical settings. The present analysis reports 24-month outcomes for patients followed up for a period of 4 years or until discontinuation. The data collection period started in October 2014. Data from patients who started IVT-AFL treatment between January 2 and October 13, 2014, were retrospectively collected and then prospectively collected from October 14, 2014, onwards. Data are collected during the initial visit and the routine follow-up visits.
Procedures
As RAINBOW is an observational study, there was no study pre-specified retreatment criteria, it was at the investigator’s discretion based on clinical expertise and routine medical practice to determine when retreatment was needed.
Participants
Patients aged ≥18 years with a diagnosis of nAMD who were treatment naïve to any anti-VEGF agent or macular laser in the study eye, which was defined as the worst-seeing eye of each patient, but the second eye was also considered if it was treatment naïve. Patients were excluded if they had another retinal disease (i.e. diabetic retinopathy, diabetic macular oedema, myopic choroidal neovascularization, retinal vein occlusion, central serous chorioretinopathy, or angioid streaks) or if they were participating in any other interventional study.
Endpoints
The primary endpoint was the change in best-corrected visual acuity (BCVA) from baseline to Month 12 as assessed by the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol or a visual logarithmic scale. These results have been previously published [6]. Results at 24 months in patients according to IVT-AFL treatment regimen are presented here. Secondary outcomes included the percentage of patients who gained more than 0, 5, 10, or 15 letters, or lost more than 15 letters at 24 months; and the proportion of patients with BCVA over and inclusive of 70 letters at 24 months. All adverse events (AEs) reported after the first injection of IVT-AFL, and up to 30 days after the last IVT-AFL injection, were documented.
Statistical analysis
Sample size calculations indicated that 600 patients needed to be enrolled in the RAINBOW study to achieve 390 usable data sets at Month 48. These estimates were based on the VIEW studies, using a 10% annual dropout rate. Visual acuity analyses were based on the full analysis set (FAS), which included patients who had documented visual acuity and anatomic assessments (in the study eye) at baseline and at least once during follow-up. The FAS-targeted group had documented visual acuity assessments in the study eye at baseline and at Month 24. The safety analysis set (SAS) comprised data from patients who received at least one IVT-AFL injection.
This 24-month analysis reports the effectiveness and safety of IVT-AFL in patients with documented visual acuity assessments at baseline and Month 24 (FAS-targeted group), stratified by IVT-AFL regimen as follows: (1) regular treatment interval cohort: patients who received three initial monthly (− 1/+ 2 weeks) IVT-AFL doses and then IVT-AFL every 2 months (− 3/+ 4 weeks) with ≥6 injections during the first 12 months; (2) irregular treatment interval cohort with three initial doses: patients who received IVT-AFL every < 2 or > 2 months with three initial doses over the first 12 months; or (3) irregular treatment interval cohort without three initial doses: including patients who received IVT-AFL every < 2 or > 2 months without three initial doses over the first 12 months. After the first 12 months, treatment frequency and modality for all cohorts was at the discretion of the treating physician and in accordance with approved local prescribing information. The statistical analysis was performed with the software package SAS, release 9.4 (SAS Institute Inc., Cary, NC, USA).
Results
Patients
Data from 514 patients who had BCVA scores at baseline and at least one follow-up assessment were included in this 24-month analysis (the FAS, or overall population). A total of 102 patients were included in the regular treatment interval cohort, and 268 and 60 patients were included in the irregular treatment interval cohorts with and without initial doses, respectively. Overall, 264 patients had documented visual acuity assessments in the study eye at baseline and Month 24 (the FAS-targeted population). Safety data were analysed from 588 patients (SAS) (Fig. 1). Patient baseline demographics and characteristics (FAS and FAS-targeted populations) are presented in Table 1. The mean (standard deviation; SD) age at enrolment was 79.6 (7.9) years and the mean (SD) duration of nAMD was 1.4 (8.7) months.
Fig. 1.
Patient disposition during the study. BCVA best-corrected visual acuity, FAS full analysis set, M0 Month zero
Table 1.
Patient demographic and baseline characteristics
| Characteristic | FAS population N = 514 | FAS-targeted population at Months 0 and 24 N = 264 |
|---|---|---|
| Age, years | 79.6 (7.9) | 79.2 (7.7) |
| Female, n (%) | 315 (61.3) | 163 (61.7) |
| Study eye, n (%) | ||
| Right | 281 (54.7) | 149 (56.4) |
| Left | 233 (45.3) | 115 (43.6) |
| Duration of nAMD, months | 1.4 (8.7) | 1.8 (11.0) |
| BCVA (letters) score at month 0 | 56.3 (18.6) | 57.3 (17.9) |
| BCVA (letters) categories, n (%) | ||
| < 50 | 143 (27.8) | 65 (24.6) |
| 50–55 | 64 (12.5) | 35 (13.3) |
| 55–70 | 151 (29.4) | 78 (29.5) |
| ≥ 70 | 156 (30.4) | 86 (32.6) |
| Intraocular pressure, mm Hg (n = 262) | 14.9 (3.1) | – |
| Diabetes, n (%) | 43 (8.4) | – |
| Hypertension, n (%) | 196 (38.1) | – |
| Cardiovascular diseases, n (%) | 87 (16.9) | – |
Mean (SD) unless otherwise stated
BCVA best-corrected visual acuity, FAS full analysis set, nAMD neovascular age-related macular degeneration, SD standard deviation
Injections and visits
Over 12 and 24 months, the mean number of IVT-AFL injections was 6.0 and 8.8, respectively; the difference in mean number indicated that there were fewer injections in the second year (Table 2). The interquartile range (Q1; Q3, 25–75% of injections) for the regular cohort was 8.0 to 13.0 injections, while for the irregular cohorts with and without initial doses was 5.0 to 12.0 and 4.0 to 11.0, respectively (Table 2). The mean number of clinic visits over 12 and 24 months was 9.3 and 15.1, respectively (Table 2). The interquartile range (Q1; Q3, 25–75% of visits) for the regular cohort was 13.0 to 19.0, while for the irregular cohorts with and without initial doses was 14.0 to 20.0 and 12.0 to 17.0 visits (Table 2).
Table 2.
IVT-AFL injections and visits over 12 and 24 months of treatment
| Overall population (FAS; n = 514) | Regular cohort (n = 102) | Irregular cohort with initial doses (n = 268) | Irregular cohort without initial doses (n = 60) | |
|---|---|---|---|---|
| IVT-AFL injections | ||||
| Mean (SD) over 12 Months | 6.0 (2.1) | 7.2 (0.8) | 6.1 (2.2) | 5.2 (1.8) |
| Mean (SD) over 24 Months | 8.8 (4.3) | 10.6 (2.8) | 9.3 (4.6) | 7.8 (3.7) |
| Min; max | 1.0; 23.0 | 6.0; 17.0 | 3.0; 23.0 | 1.0; 16.0 |
| Median | 8.0 | 11.0 | 9.0 | 8.0 |
| Q1; Q3 | 5.0; 12.0 | 8.0; 13.0 | 5.0; 12.0 | 4.0; 11.0 |
| Visits | ||||
| Mean (SD) over 12 Months | 9.3 (2.3) | 9.5 (1.8) | 10.1 (1.9) | 8.8 (1.8) |
| Mean (SD) over 24 Months | 15.1 (5.1) | 15.9 (4.2) | 16.8 (4.2) | 14.8 (3.8) |
| Min; max | 2.0; 29.0 | 8.0; 27.0 | 6.0; 29.0 | 6.0; 23.0 |
| Median | 15.0 | 16.0 | 17.0 | 15.0 |
| Q1; Q3 | 12.0; 19.0 | 13.0; 19.0 | 14.0; 20.0 | 12.0; 17.0 |
FAS full analysis set, IVT-AFL intravitreal aflibercept, n n numbers from the overall FAS population, Q1;Q3, interquartile range, SD standard deviation
Visual outcomes
The mean change in BCVA with IVT-AFL treatment over 24 months was + 3.0 letters in the overall population (P < 0.05 vs baseline). The mean change from baseline was positive for the regular and irregular treatment interval cohorts with initial doses (+ 4.9 and + 4.0 letters, respectively; P < 0.05 vs baseline for both) and negative for the irregular treatment interval cohort without initial doses (− 2.5 letters; P = 0.365) (Fig. 2). The visual gains observed with regular versus irregular IVT-AFL treatment regimens with initial doses were not statistically different (P = 0.571). The mean gain observed for the regular treatment interval cohort was significantly greater than the gain observed in the irregular treatment interval without initial dose (P = 0.036). The mean BCVA score in the overall population increased from 57.3 at baseline to 60.3 at Month 24 (Fig. 3).
Fig. 2.
Change in visual acuity over 12 and 24 months according to intravitreal aflibercept regimen. Observed analysis. *P < 0.05 versus baseline. BCVA best-corrected visual acuity, FAS full analysis set, IDs, initial doses, irreg irregular, reg regular, n number or patients
Fig. 3.
Mean BCVA score at baseline and at Month 24. FAS targeted: n = 264. Regular treatment interval cohort: n = 70. Irregular treatment interval cohort with initial doses: n = 142. Irregular treatment interval cohort without initial doses: n = 40. BCVA best-corrected visual acuity, ETDRS Early Treatment Diabetic Retinopathy Study, FAS full analysis set
The proportion of patients who experienced a gain in visual acuity letter score of ≥15 letters from the initial visit to Month 24 was 26.5% in the overall population. When broken down by treatment frequency, a gain of ≥15 letters was observed in 25.7% of the regular treatment interval cohort and 31.7% of the irregular treatment interval cohort with initial doses. The proportion of patients in the irregular treatment interval cohort without initial doses who had a gain of ≥15 letters was 10.0% (odds ratio [OR; 95% CI]): 3.95 [1.11–14.03]; P = 0.034, a significantly lower proportion than the regular treatment cohort. The odds for patients in the irregular treatment interval cohort to gain ≥15 letters in a 24-month period were five-fold greater than for patients in the irregular interval treatment cohort without initial doses (5.03 [1.53–16.61]; P = 0.008). The proportion of patients who experienced a loss in visual acuity letter score of > 15 letters from the initial visit to Month 24 was 12.1% in the overall population and 7.1% in the regular treatment interval cohorts. The proportion of patients who experienced a loss in visual acuity letter score of > 15 letters from the initial visit to Month 24 was comparable between the irregular treatment interval cohorts with initial doses (14.1%; OR [95% CI]: 0.47 [0.17–1.31]; not significant [NS]) and without initial doses (12.5%; OR [95% CI]: 0.54 [0.15–2.0]; NS), respectively. The proportion of patients in the overall population who achieved ≥70 letters according to IVT-AFL regimen is presented in Fig. 4.
Fig. 4.
Proportion of patients with a BCVA ≥70 letters by IVT-AFL regimen. Observed analysis. Regular treatment interval cohort: n = 102 (month 0); n = 102 (month 12); n = 70 (month 24). Irregular treatment interval cohort with initial doses: n = 268 (month 0); n = 268 (month 12); n = 142 (month 24). Irregular treatment interval cohort without initial doses: n = 60 (month 0); n = 60 (month 12); n = 40 (month 24). BCVA best corrected visual acuity, IVT-AFL intravitreal aflibercept
Safety
Overall, 38.4% (n/N = 226/588) of patients experienced at least one treatment-emergent adverse event (TEAE) and 10% (n = 59) experienced at least one treatment-related TEAE (Table 3). The most common ocular AEs were lack of efficacy (6.3%), vitreous floaters (2.7%), and lacrimation increased (1.7%). The most common non-ocular AEs included a product-use issue (3.1%), bronchitis (1.9%), fall (1.2%), and malaise (1.0%). Serious TEAEs were reported in 10.9% of patients. Five deaths were recorded during the study; no deaths were considered related to treatment.
Table 3.
Safety outcomes at Month 24
| Safety population (N = 588) | Total n (%) |
|---|---|
| Any TEAE | 226 (38.4) |
| Any treatment-related TEAE | 59 (10.0) |
| Ocular | 54 (9.2) |
| Non-ocular | 5 (0.9) |
| Any ocular TEAE | 136 (23.1) |
| Most common ocular AE | |
| Lack of efficacy | 37 (6.3) |
| Vitreous floaters | 16 (2.7) |
| Lacrimation increased | 10 (1.7) |
| Visual acuity reduced | 9 (1.5) |
| Retinal pigment epithelium detachment | 9 (1.5) |
| Any non-ocular TEAE | 123 (20.9) |
| Most common non-ocular AE | |
| Inappropriate schedule of drug administration | 18 (3.1) |
| Bronchitis | 11 (1.9) |
| Fall | 7 (1.2) |
| Malaise | 6 (1.0) |
| Influenza | 5 (0.9) |
| Discontinuation due to TEAE | 72 (12.2) |
| Discontinuation due to treatment-related TEAE | 40 (6.8) |
| Any serious TEAE | 64 (10.9) |
| Ocular | 9 (1.5) |
| Non-ocular | 59 (10.0) |
| Serious TEAE (> 0.5%) | |
| Transient ischemic attack | 4 (0.7) |
| Death | 5 (0.9) |
AE adverse events; TEAE treatment-emergent adverse event
Discussion
RAINBOW is an ongoing study investigating the effectiveness and safety of IVT-AFL for the management of treatment-naïve patients with nAMD in real-life clinical practice in France. In the present analysis, visual improvements were observed at Month 24 in patients with nAMD following IVT-AFL treatment, with an increase from baseline in BCVA of + 3.0 letters in the overall population. Notably, patients who received three initial monthly doses and regular IVT-AFL treatment experienced better visual outcomes over 24 months than patients with irregular treatment without initial doses. Visual gains observed with regular versus irregular IVT-AFL treatment with initial doses were not statistically different. A significant mean change from baseline in BCVA was observed in the regular and irregular treatment interval cohorts receiving initial doses, + 4.9 and + 4.0 letters, respectively, while the irregular treatment interval cohort without initial doses of IVT-AFL experienced a change of − 2.5 letters at 24 months. The findings from this analysis at 24 months are consistent with results from the initial 12-month analysis [6] and highlight the importance of three initial monthly IVT-AFL treatments to stabilize the disease and maintain visual outcomes. The change from baseline in BCVA in this analysis was not as large as in the VIEW clinical trials at Week 96 (+ 7.6 letters) [3]. In VIEW the percentage of patients gaining ≥15 letters was 33.4%, and the percentage of patients maintaining visual acuity (losing < 15 letters) was 92.4% at Week 96 in the IVT-AFL 2 mg group. It is important to note that in the VIEW studies, in Year 1 patients received three initial doses and bimonthly injections, while in Year 2 patients received an as-needed injection regimen with defined retreatment criteria and mandatory dosing at least every 12 weeks [3]. In the VIEW study, patients received a mean of 11.2 IVT-AFL injections over the 96-week period, with fewer injections in the second year (4.2 injections from Week 52 to 96) [3]. In comparison, over the analysis period in the present study, the mean number of IVT-AFL injections was 8.8 and, similar to the VIEW studies, there were fewer injections in the second year. However, in the VIEW studies patients exhibited a more severe disease (mean visual acuity at baseline = 53.6 [13.5] letters in the patients treated with IVT-AFL 2 mg bimonthly) [3] than in the RAINBOW study.
Real-world evidence from the use of IVT-AFL for the treatment of nAMD is also being collected in other countries. PERSEUS (Prospective Non-intERventional Study to asSEss the Effectiveness of Aflibercept in roUtine Clinical Practice in patientS With Wet Age-related Macular Degeneration) is a 24-month prospective observational cohort study conducted in hospitals and medical centers in Germany among treatment-naïve or previously treated patients with nAMD. Following IVT-AFL, there was a significant mean visual acuity gain at 1 year of + 6.1 letters in the population with regular treatment intervals for IVT-AFL compared with + 1.5 letters in those with irregularities in their treatment regimen [9]. An observational database study in treatment-naïve patients with nAMD from centers in Australia, New Zealand, and Switzerland was conducted by the Fight Retinal Blindness (FRB) group. Patients completed 2 years of proactive IVT-AFL treatment according to a treat-and-extend regimen. Over 2 years of treatment, a significant increase in mean visual acuity was reported (+ 6.0 letters). In the FRB study, from the first to the second year of treatment there was a decrease in the mean number of injections (7.8 vs 5.7) and visits (8.7 vs 6.5) for eyes completing 2 years of treatment [10]. In the present study, the poor visual acuity in the irregular treatment interval cohort without initial doses appears to be more likely related to few patients (10%) achieving gains ≥15 letters, patients losing > 15 letters (12.5%) and fewer treatment injections and visits over the 24 months than other treatment groups. The findings from the present study add to the real-world evidence supporting the continued use of IVT-AFL through 24 months.
Safety findings from the RAINBOW study at 24 months were consistent with the known safety profile of IVT-AFL in patients with nAMD [3, 11]. Five deaths were recorded during the study; none were considered related to treatment. The incidence of ocular AEs was lower in the present study than in VIEW studies, which may be due to possible underreporting in an observational study compared with a randomized study.
Due to the observational design of the RAINBOW study there are a number of inherent limitations that must be recognized when interpreting these findings. The use of a variety of charts to assess visual acuity may have introduced bias, especially when evaluating the number of letters gained or lost after treatment. Furthermore, the limitations of analysing the evolution of visual acuity in relation to the number of injections only must be recognized. Disease-related evolution of nAMD can occur that may not be directly influenced by treatment, even if treatment is optimal. In addition, these findings reflect real-life clinical practice in France and may not be generalisable across countries.
Conclusions
Findings from the RAINBOW study at 24 months were consistent with results from the primary endpoint at 12 months and highlight the importance of three initial monthly IVT-AFL injections on visual outcomes. Notably, treatment-naïve patients who received three initial monthly IVT-AFL doses followed by regular treatment over the first 12 months experienced better visual outcomes at 24 months compared with irregular treatment without initial doses. The overall safety profile was consistent with previous studies of IVT-AFL. The results of this 24-month analysis of the 4-year RAINBOW study were only slightly lower than those of randomized studies, such as VIEW, and demonstrate that IVT-AFL (with initial doses) offers treatment effectiveness in real-world practice.
Acknowledgements
The authors thank the patients and investigators who contributed to this study. Medical writing and editorial assistance for this article were provided by Louise Brady, PhD (Apothecom, UK) and funded by Bayer Consumer Care AG, Switzerland. All authors were responsible for and/or involved in provision of patients/data acquisition, data analysis, data review, and interpretation. These data have been previously presented at the annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), Vancouver, Canada, April 28–May 2, 2019; the 19th European Society of Retina Specialists Congress (19th EURETINA), Paris, France, September 5–8, 2019; the 2019 MaculArt Meeting, Paris, France, June 23–25, 2019 and the 125th Congrès de la Société Française d’Ophtalmologie (125th SFO), France, Paris, May 11, 2019.
Abbreviations
- AE
Adverse event
- AMD
Age-related macular degeneration
- anti-VEGF
Anti-vascular endothelial growth factor
- ARVO
Association for Research in Vision and Ophthalmology
- BCVA
Best-corrected visual acuity
- CCTIRS
Comité Consultatif sur le Traitement de l’Information en Matière de Recherche dans le Domaine de la Santé
- CNIL
Commission Nationale de l’Informatique et des Libertés
- EFPIA
European Federation of Pharmaceutical Industries and Associations
- ETDRS
Early Treatment Diabetic Retinopathy Study
- EU
European Union
- EURETINA
European Society of Retina Specialists
- FAS
Full analysis set
- FRB
Fight Retinal Blindness
- IVT-AFL
Intravitreal aflibercept
- M0
Month zero
- nAMD
Neovascular age-related macular degeneration
- n
Number of patients
- NS
Not significant
- OR
Odds ratio
- PERSEUS
Prospective Non-intERventional Study to asSEss the Effectiveness of Aflibercept in roUtine Clinical Practice in patientS With Wet Age-related Macular Degeneration
- PhRMA
Pharmaceutical Research and Manufacturers of America
- Q
Interquartile range
- RAINBOW
Real Life of intravitreal Aflibercept In FraNce: oBservatiOnal study in Wet AMD
- SAS
Safety analysis set
- SD
Standard deviation
- SFO
Société Française d’Ophtalmologie
- TEAE
Treatment-emergent adverse event
- UK
United Kingdom
- US
United States
- VIEW
VEGF Trap-Eye Investigation of Efficacy and Safety in Wet AMD
Authors’ contributions
All authors have read and approved the manuscript. MW contributed to the design; data acquisition, analysis, and interpretation; and preparation and final review of the manuscript. MD contributed to the design; data acquisition, analysis, and interpretation; and preparation and final review of the manuscript. FC contributed to the design; data acquisition, analysis, and interpretation; and preparation and final review of the manuscript. CF contributed to the design; data acquisition, analysis, and interpretation; and preparation and final review of the manuscript. SB contributed to data acquisition, analysis, interpretation, preparation, and final review of the manuscript. LK contributed to the data acquisition, analysis, interpretation, and final review of the manuscript. SYC contributed to the design; data acquisition, analysis, and interpretation; and preparation and final review of the manuscript.
Funding
The RAINBOW study was funded by Bayer HealthCare SAS, France. Bayer participated in the design of the study; analysis and interpretation of the data; and development of the manuscript. Bayer was responsible for the conduct of the study and oversight of the collection and management of data.
Availability of data and materials
Availability of the data underlying this publication will be determined according to Bayer’s commitment to the EFPIA/PhRMA “Principles for responsible clinical trial data sharing”. This pertains to scope, time point and process of data access.
As such, Bayer commits to sharing upon request from qualified scientific and medical researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the United States (US) and European Union (EU) as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014.
Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct further research that can help advance medical science or improve patient care. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.
Data access will be granted to anonymized patient-level data, protocols and clinical study reports after approval by an independent scientific review panel. Bayer is not involved in the decisions made by the independent review panel. Bayer will take all necessary measures to ensure that patient privacy is safeguarded.
Ethics approval and consent to participate
No Independent Ethics Committee and Institutional Review Board approval was obtained due to the study’s observational design in accordance with the requirements of local law and regulations in France. The protocol was reviewed and approved by a French data privacy committee: Comité Consultatif sur le Traitement de l’Information en Matière de Recherche dans le Domaine de la Santé (CCTIRS) and Commission Nationale de l’Informatique et des Libertés (CNIL). Bayer France received a positive statement from the CCTIRS on 18 June 2014 and an authorization from the CNIL on 14 October 2014 for the RAINBOW study. They gave Bayer the possibility to collect, analyze and use anonymized data of patients included in this study. All patients provided written informed consent to participate.
Consent for publication
Not applicable.
Competing interests
MW reports personal fees from Bayer, outside the submitted work; MD reports support with clinical studies from Bayer and Novartis, during the conduct of the study and outside of the submitted work; FC reports personal fees from Bayer, personal fees from Novartis, personal fees from Roche, outside the submitted work; CF reports grants from Novartis, grants from Allergan, grants from Bayer, outside the submitted work; SB reports personal fees and other from Bayer Healthcare, personal fees and other from Horus Pharma, personal fees and other from Novartis SAS, personal fees and other from Allergan SAS, outside the submitted work; LK reports grants and personal fees from Allergan, personal fees from Bayer, grants and personal fees from Novartis, outside the submitted work; SYC reports personal fees from Bayer, during the conduct of the study; personal fees from Novartis, personal fees from Bayer, personal fees from Allergan, personal fees from Thea, personal fees from Tilak, personal fees from Roche, outside the submitted work.
Footnotes
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.Ferris FL, 3rd, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol. 1984;102(11):1640–1642. doi: 10.1001/archopht.1984.01040031330019. [DOI] [PubMed] [Google Scholar]
- 2.Patel PJ, Devonport H, Sivaprasad S, Ross AH, Walters G, Gale RP, Lotery AJ, Mahmood S, Talks JS, Napier J. Aflibercept treatment for neovascular AMD beyond the first year: consensus recommendations by a UK expert roundtable panel, 2017 update. Clin Ophthalmol. 2017;11:1957–1966. doi: 10.2147/OPTH.S145732. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, Brown DM, Chong V, Nguyen QD, Ho AC, Ogura Y, Simader C, Jaffe GJ, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology. 2014;121(1):193–201. doi: 10.1016/j.ophtha.2013.08.011. [DOI] [PubMed] [Google Scholar]
- 4.Bayer: Eylea (aflibercept) Summary of Product Characteristics. Available at: https://www.emaeuropaeu/documents/product-information/eylea-epar-product-information_en.pdf August 2018.
- 5.Lanzetta Paolo, Loewenstein Anat. Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti–vascular endothelial growth factor therapy of macular diseases. Graefe's Archive for Clinical and Experimental Ophthalmology. 2017;255(7):1259–1273. doi: 10.1007/s00417-017-3647-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Weber M, Velasque L, Coscas F, Faure C, Aubry I, Cohen SY. Effectiveness and safety of intravitreal aflibercept in patients with wet age-related macular degeneration treated in routine clinical practices across France: 12-month outcomes of the RAINBOW study. BMJ Open Ophthalmol. 2019;4(1):e000109. doi: 10.1136/bmjophth-2017-000109. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Wierzbicka N, Jahnz-Różyk K. The evolving landscape for real world evidence in Poland: physicians' perspective. J Health Policy Outcomes Res. 2015;1:15–33. [Google Scholar]
- 8.Berger M, Daniel G, Frank K, Hernandez A, McClellan M, Okun S, Overhage M, Platt R, Romine M, Tunis S, et al. White paper: a framework for regulatory use of real-world evidence. 2017. [Google Scholar]
- 9.Framme C, Eter N, Hamacher T, Hasanbasic Z, Jochmann C, Johnson KT, Kahl M, Sachs H, Schilling H, Thelen U, et al. Aflibercept for patients with neovascular age-related macular degeneration in routine clinical practice in Germany: twelve month outcomes of PERSEUS. Ophthalmol Retin. 2018;2(6):539–549. doi: 10.1016/j.oret.2017.09.017. [DOI] [PubMed] [Google Scholar]
- 10.Barthelmes D, Nguyen V, Daien V, Campain A, Walton R, Guymer R, Morlet N, Hunyor AP, Essex RW, Arnold JJ, et al. Two Year Outcomes of "Treat and Extend" Intravitreal Therapy Using Aflibercept Preferentially for Neovascular Age-Related Macular Degeneration. Retina (Philadelphia, Pa) 2018;38(1):20–28. doi: 10.1097/IAE.0000000000001496. [DOI] [PubMed] [Google Scholar]
- 11.Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, Ogura Y, Yancopoulos GD, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537–2548. doi: 10.1016/j.ophtha.2012.09.006. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
Availability of the data underlying this publication will be determined according to Bayer’s commitment to the EFPIA/PhRMA “Principles for responsible clinical trial data sharing”. This pertains to scope, time point and process of data access.
As such, Bayer commits to sharing upon request from qualified scientific and medical researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the United States (US) and European Union (EU) as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014.
Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct further research that can help advance medical science or improve patient care. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.
Data access will be granted to anonymized patient-level data, protocols and clinical study reports after approval by an independent scientific review panel. Bayer is not involved in the decisions made by the independent review panel. Bayer will take all necessary measures to ensure that patient privacy is safeguarded.